• Explore /
  • Poster
  • / Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Joseph W. Kim

Yale Cancer Center, Yale School of Medicine, New Haven, CT

Joseph W. Kim , Rana R. McKay , Mary-Ellen Taplin , Nancy B. Davis , Paul Monk III, Leonard Joseph Appleman , Primo Lara Jr., Ulka N. Vaishampayan , Jingsong Zhang , Asit K. Paul , Glenn Bubley , Eliezer Mendel Van Allen , Ying Huang , Zhenwei Zhang , Massimo Loda , Geoffrey Shapiro , Patricia LoRusso , S. Percy Ivy , Daniel Peter Petrylak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02893917

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 111)

Abstract #

111

Poster Bd #

E13

Abstract Disclosures

Similar Posters

First Author: Benedito A. Carneiro

First Author: Joseph W. Kim

First Author: Navid Hafez

First Author: Zachery Reichert